- Home
- RNTX vs WIMI Comparison
RNTX vs WIMI Comparison
Compare RNTX & WIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- WIMI
- Stock Information
- Founded
- RNTX 2001
- WIMI 2015
- Country
- RNTX United States
- WIMI China
- Employees
- RNTX 11
- WIMI N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- WIMI Computer Software: Prepackaged Software
- Sector
- RNTX Health Care
- WIMI Technology
- Exchange
- RNTX Nasdaq
- WIMI Nasdaq
- Market Cap
- RNTX 34.6M
- WIMI 38.3M
- IPO Year
- RNTX N/A
- WIMI 2020
- Fundamental
- Price
- RNTX $1.39
- WIMI $4.68
- Analyst Decision
- RNTX Buy
- WIMI
- Analyst Count
- RNTX 2
- WIMI 0
- Target Price
- RNTX $10.00
- WIMI N/A
- AVG Volume (30 Days)
- RNTX 251.4K
- WIMI 491.3K
- Earning Date
- RNTX 11-13-2025
- WIMI 01-01-0001
- Dividend Yield
- RNTX N/A
- WIMI N/A
- EPS Growth
- RNTX N/A
- WIMI N/A
- EPS
- RNTX N/A
- WIMI 1.43
- Revenue
- RNTX N/A
- WIMI $61,329,146.00
- Revenue This Year
- RNTX N/A
- WIMI N/A
- Revenue Next Year
- RNTX N/A
- WIMI N/A
- P/E Ratio
- RNTX N/A
- WIMI $3.24
- Revenue Growth
- RNTX N/A
- WIMI N/A
- 52 Week Low
- RNTX $1.04
- WIMI $2.24
- 52 Week High
- RNTX $4.40
- WIMI $29.20
- Technical
- Relative Strength Index (RSI)
- RNTX 61.54
- WIMI 56.08
- Support Level
- RNTX $1.13
- WIMI $4.61
- Resistance Level
- RNTX $1.57
- WIMI $5.04
- Average True Range (ATR)
- RNTX 0.10
- WIMI 0.46
- MACD
- RNTX 0.03
- WIMI -0.03
- Stochastic Oscillator
- RNTX 62.22
- WIMI 26.12
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About WIMI WiMi Hologram Cloud Inc.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.